PD-L1.t-haNK cells
Drug Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Drug Name PD-L1.t-haNK cells
Trade Name
Synonyms PD-L1 t-haNK|Allogeneic PD-L1-t-haNK
Drug Descriptions

PD-L1.t-haNK cells are natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) that targets PD-L1, which may induce cell killing in PD-L1-expressing tumor cells resulting in decreased tumor growth (PMID: 32439799).
DrugClasses
CAS Registry Number NA
NCIT ID C174011

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Aldoxorubicin + Cyclophosphamide + Gemcitabine + Nab-paclitaxel + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells Aldoxorubicin Cyclophosphamide Gemcitabine Nab-paclitaxel Nogapendekin alfa inbakicept PD-L1.t-haNK cells 0 1
Atezolizumab + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells Atezolizumab Nogapendekin alfa inbakicept PD-L1.t-haNK cells 0 0
Avelumab + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells Avelumab Nogapendekin alfa inbakicept PD-L1.t-haNK cells 0 0
Bevacizumab + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells Bevacizumab Nogapendekin alfa inbakicept PD-L1.t-haNK cells 0 1
Cetuximab + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells Cetuximab Nogapendekin alfa inbakicept PD-L1.t-haNK cells 0 1
Cyclophosphamide + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells + Sacituzumab govitecan-hziy Cyclophosphamide Nogapendekin alfa inbakicept PD-L1.t-haNK cells Sacituzumab govitecan-hziy 0 1
Durvalumab + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells Durvalumab Nogapendekin alfa inbakicept PD-L1.t-haNK cells 0 0
Nivolumab + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells Nivolumab Nogapendekin alfa inbakicept PD-L1.t-haNK cells 0 0
Nogapendekin alfa inbakicept + PD-L1.t-haNK cells + Pembrolizumab Nogapendekin alfa inbakicept PD-L1.t-haNK cells Pembrolizumab 0 2
PD-L1.t-haNK cells PD-L1.t-haNK cells 0 1


Additional content available in Icon for CKB-BoostCKB BOOST